NWI Management LP Has $19.26 Million Position in Insmed Incorporated (NASDAQ:INSM)

NWI Management LP increased its position in Insmed Incorporated (NASDAQ:INSM - Free Report) by 186.0% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 279,000 shares of the biopharmaceutical company's stock after buying an additional 181,460 shares during the period. Insmed accounts for 0.8% of NWI Management LP's portfolio, making the stock its 19th largest holding. NWI Management LP owned 0.16% of Insmed worth $19,262,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Steward Partners Investment Advisory LLC raised its position in Insmed by 65.2% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company's stock worth $29,000 after purchasing an additional 163 shares during the last quarter. V Square Quantitative Management LLC raised its holdings in shares of Insmed by 60.3% during the fourth quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company's stock worth $45,000 after acquiring an additional 248 shares during the period. Spire Wealth Management acquired a new position in shares of Insmed during the fourth quarter worth about $47,000. Smartleaf Asset Management LLC boosted its holdings in Insmed by 98.1% during the fourth quarter. Smartleaf Asset Management LLC now owns 830 shares of the biopharmaceutical company's stock worth $57,000 after purchasing an additional 411 shares during the last quarter. Finally, Venturi Wealth Management LLC bought a new position in shares of Insmed in the 4th quarter valued at about $86,000.

Insmed Price Performance

INSM stock opened at $65.71 on Wednesday. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03. The company has a market capitalization of $11.95 billion, a PE ratio of -11.75 and a beta of 0.84. The business's fifty day moving average price is $72.17 and its 200 day moving average price is $73.26. Insmed Incorporated has a 12-month low of $21.92 and a 12-month high of $84.91.

Insmed (NASDAQ:INSM - Get Free Report) last released its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($1.42) EPS for the quarter, missing the consensus estimate of ($1.36) by ($0.06). The firm had revenue of $92.82 million during the quarter, compared to analyst estimates of $91.63 million. Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. The firm's revenue was up 22.9% on a year-over-year basis. During the same quarter last year, the business posted ($1.06) EPS. On average, sell-side analysts anticipate that Insmed Incorporated will post -4.56 EPS for the current year.

Insider Activity

In other news, CEO William Lewis sold 6,830 shares of Insmed stock in a transaction that occurred on Thursday, May 1st. The shares were sold at an average price of $72.57, for a total value of $495,653.10. Following the transaction, the chief executive officer now directly owns 233,924 shares of the company's stock, valued at $16,975,864.68. This trade represents a 2.84% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Sara Bonstein sold 18,322 shares of the stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $80.31, for a total transaction of $1,471,439.82. Following the transaction, the chief financial officer now directly owns 118,863 shares in the company, valued at $9,545,887.53. The trade was a 13.36% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 88,232 shares of company stock valued at $6,868,473. Company insiders own 3.00% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on INSM. HC Wainwright restated a "buy" rating and issued a $90.00 price objective on shares of Insmed in a research note on Monday. Bank of America boosted their price target on shares of Insmed from $92.00 to $96.00 and gave the stock a "buy" rating in a research report on Thursday, March 20th. Royal Bank of Canada reissued an "outperform" rating and set a $100.00 price target on shares of Insmed in a research report on Wednesday, March 19th. Stifel Nicolaus reduced their price target on shares of Insmed from $97.00 to $96.00 and set a "buy" rating for the company in a research report on Friday, February 21st. Finally, UBS Group lowered their price objective on Insmed from $110.00 to $109.00 and set a "buy" rating for the company in a research report on Friday, May 9th. One analyst has rated the stock with a sell rating and seventeen have issued a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $94.63.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

Want to see what other hedge funds are holding INSM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insmed Incorporated (NASDAQ:INSM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.